The CIP2A Knockout HeLa Cell Line is a CRISPR/Cas9-edited human cell line in which the CIP2A gene has been disrupted. This loss-of-function model provides a genetically defined system to investigate the tumor-suppressor regulatory network governed by the oncoprotein CIP2A. The product is supplied as a validated HeLa-derived cell line suitable for downstream functional assays including protein analysis, gene expression profiling, and drug response studies.
The host cell line, HeLa, is an immortalized human cervical adenocarcinoma epithelial cell line. Originally derived from a cervical cancer biopsy, HeLa cells are HPV18-positive and exhibit an aneuploid karyotype. This widely used model retains key signaling pathways relevant to cancer biology, including robust MAPK/ERK and PI3K/AKT/mTOR activity. Its well-characterized genetic background and high transfection efficiency make it a reliable platform for CRISPR/Cas9-mediated gene disruption and subsequent functional interrogation of oncogenic mechanisms.
CIP2A functions as an endogenous inhibitor of protein phosphatase 2A (PP2A), a major tumor suppressor. By binding to and inhibiting PP2A, CIP2A prevents dephosphorylation of PP2A targets, most notably the oncogenic transcription factor c-Myc, thereby stabilizing c-Myc and promoting its transcriptional activity. CIP2A expression is positively regulated by the EGFR-MEK/ERK cascade, JNK, and the transcription factor E2F1, while DNA damage and Chk1 activity can modulate its levels. In addition to c-Myc, CIP2A influences downstream effectors such as AKT and MDM2, reinforcing proliferative and anti-apoptotic pathways. CIP2A also interacts with PP2A regulatory proteins SET and PME-1, further modulating PP2A activity. Thus, CIP2A acts as a central node in a signaling network that integrates growth factor, stress, and cell cycle signals to control cell fate through the CIP2A-PP2A-c-Myc axis, with connections to the PI3K/AKT/mTOR, MAPK/ERK, and JNK pathways.
In the HeLa host cell background, CIP2A is expressed and functionally contributes to the transformed phenotype. Disruption of CIP2A in this model is expected to relieve PP2A inhibition, leading to enhanced dephosphorylation of c-Myc and attenuation of downstream survival signaling. Consequently, CIP2A knockout HeLa cells exhibit reduced proliferation and heightened susceptibility to apoptotic stimuli. This phenotype makes the line particularly useful for dissecting mechanisms of oncogene addiction and identifying synthetic lethal interactions dependent on the CIP2A-PP2A-c-Myc axis.
This knockout cell line supports a range of research applications. It can be used to study CIP2A-dependent signaling via Western blotting of c-Myc, phosphorylated AKT, and PP2A substrates, and RT-qPCR of transcriptional targets. Functional assays such as PP2A activity measurements, cell viability assays, and apoptosis detection enable quantitative assessment. Colony formation assays reveal clonogenic growth, and drug sensitivity screening evaluates chemoresistance, relevant to breast, lung, colorectal, gastric, cervical cancers and acute myeloid leukemia. The line also supports CIP2A-targeted therapeutic evaluation and interaction studies with other oncogenic drivers. For technical support or custom applications, please contact Ascent Research.
